SYNTARA LIMITED - Announcements

Market Cap $27.46M Add to my watchlist

Healthcare

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug... Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

SNT	Pharmaxis Presents New Analyses of Pooled CF Data at EU Meet	PRICE SENSITIVE	18/06/13	124.41KB	Share
SNT	Aridol FDA Import Restrictions	PRICE SENSITIVE	03/06/13	115.63KB	Share
SNT	Outcome of Business Review	PRICE SENSITIVE	28/05/13	137.37KB	Share
SNT	Pharmaxis Appoints Bronchitol Distributor for Poland	PRICE SENSITIVE	22/05/13	109.57KB	Share
SNT	FDA Meeting, Business Review Announcement End of May	PRICE SENSITIVE	14/05/13	121.28KB	Share
SNT	PHASE 3 CLINICAL TRIAL IN BRONCHIECTASIS (B305)	PRICE SENSITIVE	24/04/13	110.13KB	Share
SNT	Trading Halt	PRICE SENSITIVE	22/04/13	53.59KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	10/04/13	109.59KB	Share
SNT	PHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDA	PRICE SENSITIVE	19/03/13	103.65KB	Share
SNT	Trading Halt	PRICE SENSITIVE	19/03/13	53.73KB	Share
SNT	Pharmaxis Appoints Gary Phillips New Chief Executive Officer	PRICE SENSITIVE	12/03/13	114.99KB	Share
SNT	Bronchiectasis Phase 3 Trial Milestone	PRICE SENSITIVE	08/03/13	93.9KB	Share
SNT	Half Year Report and Accounts	PRICE SENSITIVE	15/02/13	217.67KB	Share
SNT	Pharmaxis Announces US$40 million Financing Areement	PRICE SENSITIVE	31/01/13	85.06KB	Share
SNT	Pharmaxis Receives Negative Recommendation from PADAC	PRICE SENSITIVE	31/01/13	114.67KB	Share
SNT	Trading Halt	PRICE SENSITIVE	29/01/13	55.06KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	23/01/13	109.27KB	Share
SNT	IMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UK	PRICE SENSITIVE	26/10/12	85.26KB	Share
SNT	Trading Halt	PRICE SENSITIVE	26/10/12	41.95KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	10/10/12	109.01KB	Share
SNT	Response to ASX Price Query	PRICE SENSITIVE	08/10/12	161.43KB	Share
SNT	Pharmaxis Receives Maximum Extension to German Patent	PRICE SENSITIVE	27/09/12	80.57KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	10/08/12	265.62KB	Share
SNT	US FDA Accepts Bronchitol New Drug Application for Review	PRICE SENSITIVE	02/08/12	80.48KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	17/07/12	109.23KB	Share
SNT	Additional Data Bronchitol Reduces Risk of Exacerbations	PRICE SENSITIVE	08/06/12	109.51KB	Share
SNT	Bronchitol Commercial Progress in Europe	PRICE SENSITIVE	01/06/12	132.55KB	Share
SNT	Pharmaxis Submits US New Drug Application for Bronchitol	PRICE SENSITIVE	21/05/12	83.46KB	Share
SNT	Pharmaxis Receives Approval to Market Bronchitol in the EU	PRICE SENSITIVE	20/04/12	82.13KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	18/04/12	109.33KB	Share
SNT	PXS Completes Phase II study with ASM8 in asthma patients	PRICE SENSITIVE	17/04/12	108.62KB	Share
SNT	Pharmaxis Announces Agreement for EU Supply of Bronchitol	PRICE SENSITIVE	29/03/12	80.08KB	Share
SNT	European Regulatiry Update on Bronchitol	PRICE SENSITIVE	16/03/12	78.65KB	Share
SNT	Bronchitol to be Reimbursed in Australia	PRICE SENSITIVE	14/03/12	83.48KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	03/02/12	267.62KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	24/01/12	109.24KB	Share
SNT	Pharmaxis Files PBAC Minor Resubmission for Bronchitol	PRICE SENSITIVE	20/12/11	78.36KB	Share
SNT	Phase 3 Trial in Bronchiectasis Reaches Recruitment Target	PRICE SENSITIVE	13/12/11	106.04KB	Share
SNT	Retail Offer Booklet	PRICE SENSITIVE	24/11/11	2.1MB	Share
SNT	Institutional Component of Entitlement Offer	PRICE SENSITIVE	18/11/11	96.82KB	Share
SNT	Trading Halt	PRICE SENSITIVE	16/11/11	67.05KB	Share
SNT	Pharmaxis Announces PBAC Decision on Bronchitol	PRICE SENSITIVE	09/11/11	80.69KB	Share
SNT	Reinstatement to Official Quotation	PRICE SENSITIVE	24/10/11	28.28KB	Share
SNT	Pharmaxis Announces Positive Bronchitol Opinion for Europe	PRICE SENSITIVE	24/10/11	104KB	Share
SNT	Suspension from Official Quotation	PRICE SENSITIVE	20/10/11	151KB	Share
SNT	Trading Halt	PRICE SENSITIVE	17/10/11	67.36KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	12/10/11	109.05KB	Share
SNT	Phase II Trial in Allergic Asthma Completes Recruitment	PRICE SENSITIVE	29/09/11	90.81KB	Share
SNT	Update on EU Bronchitol Marketing Application	PRICE SENSITIVE	28/09/11	91.48KB	Share
SNT	Re-examination Documents Filed for EU Bronchitol Application	PRICE SENSITIVE	22/08/11	87.05KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	12/08/11	250.07KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	20/07/11	109.3KB	Share
SNT	Bronchitol Resubmitted to Australian PBAC	PRICE SENSITIVE	12/07/11	85.36KB	Share
SNT	Re-examination of Bronchitol Marketing Application Requested	PRICE SENSITIVE	05/07/11	87.84KB	Share
SNT	EU Marketing Authorisation Application Review of Bronchitol	PRICE SENSITIVE	27/06/11	87.3KB	Share
SNT	EU CHMP Confirms Negative Trend Vote on Bronchitol	PRICE SENSITIVE	24/06/11	82.97KB	Share
SNT	Response to ASX Query Letter	PRICE SENSITIVE	31/05/11	112.01KB	Share
SNT	Pharmaxis Receives Negative Bronchitol Trend Vote from CHMP	PRICE SENSITIVE	25/05/11	88.52KB	Share
SNT	Trading Halt	PRICE SENSITIVE	23/05/11	155.43KB	Share
SNT	Bronchitol Deferred by Australian PBAC	PRICE SENSITIVE	21/04/11	80.81KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	13/04/11	108.88KB	Share
SNT	Australian TGA Approves Bronchitol for Cystic Fibrosis	PRICE SENSITIVE	08/02/11	81.67KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	04/02/11	161.09KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	25/01/11	108.89KB	Share
SNT	EU Bronchitol Marketing Application Update	PRICE SENSITIVE	25/01/11	77.59KB	Share
SNT	Bronchitol EU Marketing Authorisation Update	PRICE SENSITIVE	20/12/10	78.68KB	Share
SNT	Extended Benefit with Bronchitol in Second PhaseIII CF Trial	PRICE SENSITIVE	16/12/10	80.73KB	Share
SNT	Bronchitol Recommended for Approval by Australian Advisory C	PRICE SENSITIVE	13/12/10	225.12KB	Share
SNT	Phase II Trial of ASM8 in Asthma Commences	PRICE SENSITIVE	07/12/10	91.42KB	Share
SNT	Pharmaxis Announces Positive Combined Phase 3 CF Results	PRICE SENSITIVE	22/10/10	90.37KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	13/10/10	109.71KB	Share
SNT	US FDA APPROVES ARIDOL	PRICE SENSITIVE	06/10/10	82.52KB	Share
SNT	Agreement for European Marketing of Bronchitol	PRICE SENSITIVE	31/08/10	77.65KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	21/07/10	110.79KB	Share
SNT	Results for Second Phase 3 Trial of Bronchitol in CF	PRICE SENSITIVE	22/06/10	94.43KB	Share
SNT	Trading Halt	PRICE SENSITIVE	21/06/10	93.7KB	Share
SNT	Sustained Benefit Following 18 Month Bronchitol Treatment	PRICE SENSITIVE	17/05/10	45.53KB	Share
SNT	Appendix 4C - quarterly March 2010	PRICE SENSITIVE	14/04/10	116.43KB	Share
SNT	Pharmaxis Announces Milestone in Phase 3 Trial for CF	PRICE SENSITIVE	14/04/10	25.5KB	Share
SNT	Pharmaxis Completes Phase II Clinical Study with ASM8	PRICE SENSITIVE	11/03/10	106.53KB	Share
SNT	Pharmaxis completes clinical trial with PXS25	PRICE SENSITIVE	09/02/10	30.49KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	05/02/10	548.45KB	Share
SNT	Appendix 4C - Quarterly Cash Flow	PRICE SENSITIVE	27/01/10	109.9KB	Share
SNT	Pharmaxis to acquire Canadian company TOPIGEN Pharmaceutical	PRICE SENSITIVE	12/01/10	29.99KB	Share
SNT	Pharmaxis receives response letter from the FDA on Aridol	PRICE SENSITIVE	29/12/09	63.73KB	Share
SNT	Pharmaxis lodges TGA application to market Bronchitol for CF	PRICE SENSITIVE	17/12/09	24.45KB	Share
SNT	PHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOL	PRICE SENSITIVE	02/12/09	28.24KB	Share
SNT	Pharmaxis Applies to Market Bronchitol for CF in Europe	PRICE SENSITIVE	29/10/09	23.8KB	Share
SNT	Commencement of Bronchiectasis Study and Aligning Strategy	PRICE SENSITIVE	23/10/09	25.37KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	14/10/09	109.65KB	Share
SNT	Second CF Trial Passes Recruitment Target	PRICE SENSITIVE	18/09/09	25.01KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	14/08/09	210.62KB	Share
SNT	Appendix 4C - Quarterly Cash Flow	PRICE SENSITIVE	22/07/09	109.92KB	Share
SNT	Phase 3 CF Trial Results Presented at European Conference	PRICE SENSITIVE	16/06/09	34.86KB	Share
SNT	Pharmaxis Announces Placement of $47 Million and SPP	PRICE SENSITIVE	04/06/09	24.23KB	Share
SNT	Trading Halt	PRICE SENSITIVE	02/06/09	63.42KB	Share
SNT	US FDA Accepts Aridol New Drug Application for Review	PRICE SENSITIVE	14/05/09	25.36KB	Share
SNT	Pharmaxis Announces Positive Results of Phase 3 CF Trial	PRICE SENSITIVE	04/05/09	36.75KB	Share
SNT	Trading Halt	PRICE SENSITIVE	04/05/09	58.96KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	08/04/09	56.82KB	Share

SNTPharmaxis Presents New Analyses of Pooled CF Data at EU Meet
18/06/13	PRICE SENSITIVE	124.41KB	Share
SNTAridol FDA Import Restrictions
03/06/13	PRICE SENSITIVE	115.63KB	Share
SNTOutcome of Business Review
28/05/13	PRICE SENSITIVE	137.37KB	Share
SNTPharmaxis Appoints Bronchitol Distributor for Poland
22/05/13	PRICE SENSITIVE	109.57KB	Share
SNTFDA Meeting, Business Review Announcement End of May
14/05/13	PRICE SENSITIVE	121.28KB	Share
SNTPHASE 3 CLINICAL TRIAL IN BRONCHIECTASIS (B305)
24/04/13	PRICE SENSITIVE	110.13KB	Share
SNTTrading Halt
22/04/13	PRICE SENSITIVE	53.59KB	Share
SNTAppendix 4C - quarterly
10/04/13	PRICE SENSITIVE	109.59KB	Share
SNTPHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDA
19/03/13	PRICE SENSITIVE	103.65KB	Share
SNTTrading Halt
19/03/13	PRICE SENSITIVE	53.73KB	Share
SNTPharmaxis Appoints Gary Phillips New Chief Executive Officer
12/03/13	PRICE SENSITIVE	114.99KB	Share
SNTBronchiectasis Phase 3 Trial Milestone
08/03/13	PRICE SENSITIVE	93.9KB	Share
SNTHalf Year Report and Accounts
15/02/13	PRICE SENSITIVE	217.67KB	Share
SNTPharmaxis Announces US$40 million Financing Areement
31/01/13	PRICE SENSITIVE	85.06KB	Share
SNTPharmaxis Receives Negative Recommendation from PADAC
31/01/13	PRICE SENSITIVE	114.67KB	Share
SNTTrading Halt
29/01/13	PRICE SENSITIVE	55.06KB	Share
SNTAppendix 4C - quarterly
23/01/13	PRICE SENSITIVE	109.27KB	Share
SNTIMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UK
26/10/12	PRICE SENSITIVE	85.26KB	Share
SNTTrading Halt
26/10/12	PRICE SENSITIVE	41.95KB	Share
SNTAppendix 4C - quarterly
10/10/12	PRICE SENSITIVE	109.01KB	Share
SNTResponse to ASX Price Query
08/10/12	PRICE SENSITIVE	161.43KB	Share
SNTPharmaxis Receives Maximum Extension to German Patent
27/09/12	PRICE SENSITIVE	80.57KB	Share
SNTPreliminary Final Report
10/08/12	PRICE SENSITIVE	265.62KB	Share
SNTUS FDA Accepts Bronchitol New Drug Application for Review
02/08/12	PRICE SENSITIVE	80.48KB	Share
SNTAppendix 4C - quarterly
17/07/12	PRICE SENSITIVE	109.23KB	Share
SNTAdditional Data Bronchitol Reduces Risk of Exacerbations
08/06/12	PRICE SENSITIVE	109.51KB	Share
SNTBronchitol Commercial Progress in Europe
01/06/12	PRICE SENSITIVE	132.55KB	Share
SNTPharmaxis Submits US New Drug Application for Bronchitol
21/05/12	PRICE SENSITIVE	83.46KB	Share
SNTPharmaxis Receives Approval to Market Bronchitol in the EU
20/04/12	PRICE SENSITIVE	82.13KB	Share
SNTAppendix 4C - quarterly
18/04/12	PRICE SENSITIVE	109.33KB	Share
SNTPXS Completes Phase II study with ASM8 in asthma patients
17/04/12	PRICE SENSITIVE	108.62KB	Share
SNTPharmaxis Announces Agreement for EU Supply of Bronchitol
29/03/12	PRICE SENSITIVE	80.08KB	Share
SNTEuropean Regulatiry Update on Bronchitol
16/03/12	PRICE SENSITIVE	78.65KB	Share
SNTBronchitol to be Reimbursed in Australia
14/03/12	PRICE SENSITIVE	83.48KB	Share
SNTHalf Yearly Report and Accounts
03/02/12	PRICE SENSITIVE	267.62KB	Share
SNTAppendix 4C - quarterly
24/01/12	PRICE SENSITIVE	109.24KB	Share
SNTPharmaxis Files PBAC Minor Resubmission for Bronchitol
20/12/11	PRICE SENSITIVE	78.36KB	Share
SNTPhase 3 Trial in Bronchiectasis Reaches Recruitment Target
13/12/11	PRICE SENSITIVE	106.04KB	Share
SNTRetail Offer Booklet
24/11/11	PRICE SENSITIVE	2.1MB	Share
SNTInstitutional Component of Entitlement Offer
18/11/11	PRICE SENSITIVE	96.82KB	Share
SNTTrading Halt
16/11/11	PRICE SENSITIVE	67.05KB	Share
SNTPharmaxis Announces PBAC Decision on Bronchitol
09/11/11	PRICE SENSITIVE	80.69KB	Share
SNTReinstatement to Official Quotation
24/10/11	PRICE SENSITIVE	28.28KB	Share
SNTPharmaxis Announces Positive Bronchitol Opinion for Europe
24/10/11	PRICE SENSITIVE	104KB	Share
SNTSuspension from Official Quotation
20/10/11	PRICE SENSITIVE	151KB	Share
SNTTrading Halt
17/10/11	PRICE SENSITIVE	67.36KB	Share
SNTAppendix 4C - quarterly
12/10/11	PRICE SENSITIVE	109.05KB	Share
SNTPhase II Trial in Allergic Asthma Completes Recruitment
29/09/11	PRICE SENSITIVE	90.81KB	Share
SNTUpdate on EU Bronchitol Marketing Application
28/09/11	PRICE SENSITIVE	91.48KB	Share
SNTRe-examination Documents Filed for EU Bronchitol Application
22/08/11	PRICE SENSITIVE	87.05KB	Share
SNTPreliminary Final Report
12/08/11	PRICE SENSITIVE	250.07KB	Share
SNTAppendix 4C - quarterly
20/07/11	PRICE SENSITIVE	109.3KB	Share
SNTBronchitol Resubmitted to Australian PBAC
12/07/11	PRICE SENSITIVE	85.36KB	Share
SNTRe-examination of Bronchitol Marketing Application Requested
05/07/11	PRICE SENSITIVE	87.84KB	Share
SNTEU Marketing Authorisation Application Review of Bronchitol
27/06/11	PRICE SENSITIVE	87.3KB	Share
SNTEU CHMP Confirms Negative Trend Vote on Bronchitol
24/06/11	PRICE SENSITIVE	82.97KB	Share
SNTResponse to ASX Query Letter
31/05/11	PRICE SENSITIVE	112.01KB	Share
SNTPharmaxis Receives Negative Bronchitol Trend Vote from CHMP
25/05/11	PRICE SENSITIVE	88.52KB	Share
SNTTrading Halt
23/05/11	PRICE SENSITIVE	155.43KB	Share
SNTBronchitol Deferred by Australian PBAC
21/04/11	PRICE SENSITIVE	80.81KB	Share
SNTAppendix 4C - quarterly
13/04/11	PRICE SENSITIVE	108.88KB	Share
SNTAustralian TGA Approves Bronchitol for Cystic Fibrosis
08/02/11	PRICE SENSITIVE	81.67KB	Share
SNTHalf Yearly Report and Accounts
04/02/11	PRICE SENSITIVE	161.09KB	Share
SNTAppendix 4C - quarterly
25/01/11	PRICE SENSITIVE	108.89KB	Share
SNTEU Bronchitol Marketing Application Update
25/01/11	PRICE SENSITIVE	77.59KB	Share
SNTBronchitol EU Marketing Authorisation Update
20/12/10	PRICE SENSITIVE	78.68KB	Share
SNTExtended Benefit with Bronchitol in Second PhaseIII CF Trial
16/12/10	PRICE SENSITIVE	80.73KB	Share
SNTBronchitol Recommended for Approval by Australian Advisory C
13/12/10	PRICE SENSITIVE	225.12KB	Share
SNTPhase II Trial of ASM8 in Asthma Commences
07/12/10	PRICE SENSITIVE	91.42KB	Share
SNTPharmaxis Announces Positive Combined Phase 3 CF Results
22/10/10	PRICE SENSITIVE	90.37KB	Share
SNTAppendix 4C - quarterly
13/10/10	PRICE SENSITIVE	109.71KB	Share
SNTUS FDA APPROVES ARIDOL
06/10/10	PRICE SENSITIVE	82.52KB	Share
SNTAgreement for European Marketing of Bronchitol
31/08/10	PRICE SENSITIVE	77.65KB	Share
SNTAppendix 4C - quarterly
21/07/10	PRICE SENSITIVE	110.79KB	Share
SNTResults for Second Phase 3 Trial of Bronchitol in CF
22/06/10	PRICE SENSITIVE	94.43KB	Share
SNTTrading Halt
21/06/10	PRICE SENSITIVE	93.7KB	Share
SNTSustained Benefit Following 18 Month Bronchitol Treatment
17/05/10	PRICE SENSITIVE	45.53KB	Share
SNTAppendix 4C - quarterly March 2010
14/04/10	PRICE SENSITIVE	116.43KB	Share
SNTPharmaxis Announces Milestone in Phase 3 Trial for CF
14/04/10	PRICE SENSITIVE	25.5KB	Share
SNTPharmaxis Completes Phase II Clinical Study with ASM8
11/03/10	PRICE SENSITIVE	106.53KB	Share
SNTPharmaxis completes clinical trial with PXS25
09/02/10	PRICE SENSITIVE	30.49KB	Share
SNTHalf Yearly Report and Accounts
05/02/10	PRICE SENSITIVE	548.45KB	Share
SNTAppendix 4C - Quarterly Cash Flow
27/01/10	PRICE SENSITIVE	109.9KB	Share
SNTPharmaxis to acquire Canadian company TOPIGEN Pharmaceutical
12/01/10	PRICE SENSITIVE	29.99KB	Share
SNTPharmaxis receives response letter from the FDA on Aridol
29/12/09	PRICE SENSITIVE	63.73KB	Share
SNTPharmaxis lodges TGA application to market Bronchitol for CF
17/12/09	PRICE SENSITIVE	24.45KB	Share
SNTPHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOL
02/12/09	PRICE SENSITIVE	28.24KB	Share
SNTPharmaxis Applies to Market Bronchitol for CF in Europe
29/10/09	PRICE SENSITIVE	23.8KB	Share
SNTCommencement of Bronchiectasis Study and Aligning Strategy
23/10/09	PRICE SENSITIVE	25.37KB	Share
SNTAppendix 4C - quarterly
14/10/09	PRICE SENSITIVE	109.65KB	Share
SNTSecond CF Trial Passes Recruitment Target
18/09/09	PRICE SENSITIVE	25.01KB	Share
SNTPreliminary Final Report
14/08/09	PRICE SENSITIVE	210.62KB	Share
SNTAppendix 4C - Quarterly Cash Flow
22/07/09	PRICE SENSITIVE	109.92KB	Share
SNTPhase 3 CF Trial Results Presented at European Conference
16/06/09	PRICE SENSITIVE	34.86KB	Share
SNTPharmaxis Announces Placement of $47 Million and SPP
04/06/09	PRICE SENSITIVE	24.23KB	Share
SNTTrading Halt
02/06/09	PRICE SENSITIVE	63.42KB	Share
SNTUS FDA Accepts Aridol New Drug Application for Review
14/05/09	PRICE SENSITIVE	25.36KB	Share
SNTPharmaxis Announces Positive Results of Phase 3 CF Trial
04/05/09	PRICE SENSITIVE	36.75KB	Share
SNTTrading Halt
04/05/09	PRICE SENSITIVE	58.96KB	Share
SNTAppendix 4C - quarterly
08/04/09	PRICE SENSITIVE	56.82KB	Share

REFRESH

First 2 3

(20min delay)
Last 2.3¢		Change -0.001(4.17%)		Mkt cap ! $27.46M

Open	High	Low	Value	Volume
2.4¢	2.4¢	2.2¢	$36.31K	1.599M

Buyers (Bids)

No.	Vol.	Price($)
5	793867	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.4¢	242619	3

View Market Depth

No.	Vol.	Price($)
5	793867	0.021
14	3542674	0.020
4	1315798	0.019
3	1002999	0.018
6	578189	0.017

Price($)	Vol.	No.
0.024	242619	3
0.025	103870	3
0.026	50000	1
0.027	200000	1
0.028	500000	1

Last trade - 15.46pm 25/06/2024 (20 minute delay)


Last 2.2¢		Change -0.001 ( 8.33 %)
Open	High	Low	Volume
2.2¢	2.3¢	2.2¢	209216
Last updated 15.34pm 25/06/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available